Inheritance and the Impact on Your Family
At a Glance
ADTKD-UMOD is inherited in an autosomal dominant pattern: each child of a person with a disease-causing UMOD variant has a 50% chance of inheriting it. Genetic counseling and targeted family testing can guide monitoring, kidney donation, and family-planning decisions.
Because ADTKD-UMOD is a genetic condition, your diagnosis has implications that reach beyond your own health. Understanding how the disease is passed down and how it might affect your relatives is the first step in protecting your family’s future [1].
The 50/50 Rule: Autosomal Dominant Inheritance
ADTKD-UMOD follows a pattern called autosomal dominant inheritance. This means that a person only needs one mutated copy of the UMOD gene to develop the disease [2].
- The Odds: For every pregnancy, there is a 50% chance (1 in 2) that the mutation will be passed to the child [3].
- No “Skip”: The inheritance pattern does not “skip” generations. If a child does not inherit the mutation, they cannot pass it on to their own children. However, the clinical signs may appear to skip a generation because of late onset, variable severity, or an unrecognized affected parent [1].
- “De Novo” Cases: In some cases, a person may be the first in their family to have the mutation. This is called a de novo mutation, meaning it started with you rather than being inherited from a parent [4][5].
Men vs. Women: Differences in Progression
While both men and women inherit the gene at the same rate, the disease often moves faster in men [6].
- Timing of Kidney Failure: In large studies, the median age for reaching kidney failure was 47 years [6].
- The “Gap”: On average in these cohorts, men tend to reach this stage about four years earlier than women with the same mutation [7].
- Variability: It is important to remember that these are averages. In any given family, one person might reach kidney failure at age 30 while another remains healthy into their 70s [4][8]. Current science cannot reliably predict an individual’s exact age of kidney failure from sex or UMOD variant alone.
Why Your Specific Mutation Matters
Not all UMOD mutations are created equal. The speed of your kidney decline is often linked to how severely the mutation causes the uromodulin protein to get “stuck” inside your cells [6][9].
- “Milder” Variants: Some specific mutations, like one called p.Thr62Pro, are known to cause a slower decline in some research observations [8].
- Predictive Testing: Scientists use lab scores to measure how much a mutation disrupts protein traffic. These scores are currently experimental research tools, not validated tests that reliably predict your individual outcome [6].
Knowing Your Subtype: Typical Clues
When you tell doctors you have ADTKD, they may check your records for other subtypes. Having a confirmed UMOD mutation explains your diagnosis, but here are the typical clues of other subtypes:
- ADTKD-MUC1: Often looks identical to UMOD but usually doesn’t cause gout [10]. It requires a very specialized genetic test [11].
- ADTKD-REN: Often starts in childhood and can cause low blood pressure, anemia, and high potassium [12][2].
- ADTKD-HNF1B: Often involves other organs, such as the pancreas (causing diabetes) or structural issues like cysts or unusual kidney shapes [13][14].
Family Planning and Future Generations
If you are planning to start or grow a family, preconception counseling is important.
- Preimplantation Genetic Testing (PGT-M): This involves using IVF (In Vitro Fertilization) to test embryos for the UMOD mutation before they are implanted, to reduce the chance of transmitting the known variant. It requires test development, genetic counseling, and does not guarantee a healthy pregnancy or child [15].
- Natural Conception: Many families choose natural conception. However, chronic kidney disease can increase risks of maternal hypertension, preeclampsia, fetal-growth restriction, and kidney-function decline [16]. Preconception review with your nephrology team and maternal-fetal medicine is strongly recommended.
Cascade Testing: Reaching Out to Relatives
“Cascade testing” is the process of offering targeted testing to at-risk relatives once a mutation is found in the family [17].
- Who to Test: Testing usually starts with “first-degree” relatives—parents, siblings, and adult children [18].
- The Benefit: Most people (93%) who are found to have the mutation through family testing say they are glad they did it [18]. It allows for early monitoring and is vital for identifying who can safely serve as a kidney donor [17][18].
- Counseling: Independent genetic counseling should precede testing to discuss the right not to know, privacy concerns, potential impacts on life or disability insurance, and to protect family members from undue pressure regarding living donation.
- Minors: Testing children is a personal decision. While the disease rarely causes major issues in early childhood, knowing a child’s status can help avoid “diagnostic odysseys” if they develop gout or high uric acid as teenagers [5][2].
Common questions in this guide
What is the chance of passing ADTKD-UMOD to my child?
Can ADTKD-UMOD skip a generation?
Should my relatives get tested for the UMOD variant?
Can my UMOD variant predict when my kidneys will fail?
What family-planning options are available if I have ADTKD-UMOD?
When should a child in an ADTKD-UMOD family be tested?
Should a potential living kidney donor in my family have UMOD testing?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my specific UMOD mutation, does the research suggest a faster or slower progression compared to the median age of 47?
- 2.Can you refer me to a genetic counselor to discuss the risk to my children and options for family planning?
- 3.Should my siblings or adult children be screened with a genetic test, even if their blood work currently looks normal?
- 4.If we decide to test my children, at what age should that begin, and what would we do differently if the test is positive?
- 5.How can we ensure that any family members who want to be kidney donors are tested for my specific mutation first?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (18)
- 1
Autosomal Dominant Tubulointerstitial Kidney Disease.
Bleyer AJ, Kidd K, Živná M, Kmoch S
Advances in chronic kidney disease 2017; (24(2)):86-93 doi:10.1053/j.ackd.2016.11.012.
PMID: 28284384 - 2
Autosomal dominant tubulointerstitial kidney disease: A review.
Živná M, Kidd KO, Barešová V, et al.
American journal of medical genetics. Part C, Seminars in medical genetics 2022; (190(3)):309-324 doi:10.1002/ajmg.c.32008.
PMID: 36250282 - 3
Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report.
Eckardt KU, Alper SL, Antignac C, et al.
Kidney international 2015; (88(4)):676-83 doi:10.1038/ki.2015.28.
PMID: 25738250 - 4
ADTKD-UMOD in a girl with a de novo mutation: A case report.
Li MS, Li Y, Jiang L, et al.
Frontiers in medicine 2022; (9()):1077655 doi:10.3389/fmed.2022.1077655.
PMID: 36606057 - 5
Early-onset kidney failure in a girl with autosomal dominant tubulointerstitial kidney disease due to a de novo UMOD variant.
Tomori S, Miura K, Shirai Y, et al.
CEN case reports 2026; (15(2)):46 doi:10.1007/s13730-025-01081-3.
PMID: 41642419 - 6
Genetic and Clinical Predictors of Age of ESKD in Individuals With Autosomal Dominant Tubulointerstitial Kidney Disease Due to UMOD Mutations.
Kidd K, Vylet'al P, Schaeffer C, et al.
Kidney international reports 2020; (5(9)):1472-1485 doi:10.1016/j.ekir.2020.06.029.
PMID: 32954071 - 7
Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progression.
Ramesh SS, Rogge M, Kidd KO, et al.
Journal of pharmacokinetics and pharmacodynamics 2025; (52(4)):41.
PMID: 40707830 - 8
An intermediate-effect size variant in UMOD confers risk for chronic kidney disease.
Olinger E, Schaeffer C, Kidd K, et al.
Proceedings of the National Academy of Sciences of the United States of America 2022; (119(33)):e2114734119 doi:10.1073/pnas.2114734119.
PMID: 35947615 - 9
Allelic effects on uromodulin aggregates drive autosomal dominant tubulointerstitial kidney disease.
Schiano G, Lake J, Mariniello M, et al.
EMBO molecular medicine 2023; (15(12)):e18242 doi:10.15252/emmm.202318242.
PMID: 37885358 - 10
Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1.
Ayasreh N, Bullich G, Miquel R, et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (72(3)):411-418 doi:10.1053/j.ajkd.2018.03.019.
PMID: 29784615 - 11
Autosomal Dominant Tubulointerstitial Kidney Disease Due to UMOD Mutation: A Two-Case Report and Literature Review.
Liang D, Liang S, Zhang M, et al.
Nephron 2019; (143(4)):282-287 doi:10.1159/000502146.
PMID: 31422399 - 12
An international cohort study of autosomal dominant tubulointerstitial kidney disease due to REN mutations identifies distinct clinical subtypes.
Živná M, Kidd K, Zaidan M, et al.
Kidney international 2020; (98(6)):1589-1604 doi:10.1016/j.kint.2020.06.041.
PMID: 32750457 - 13
Variable Expressivity of HNF1B Nephropathy, From Renal Cysts and Diabetes to Medullary Sponge Kidney Through Tubulo-interstitial Kidney Disease.
Izzi C, Dordoni C, Econimo L, et al.
Kidney international reports 2020; (5(12)):2341-2350 doi:10.1016/j.ekir.2020.09.042.
PMID: 33305128 - 14
Autosomal dominant tubulointerstitial kidney disease: more than just HNF1β.
Bleyer AJ, Wolf MT, Kidd KO, et al.
Pediatric nephrology (Berlin, Germany) 2022; (37(5)):933-946 doi:10.1007/s00467-021-05118-4.
PMID: 34021396 - 15
A comprehensive PGT-M strategy for ADPKD patients with de novo PKD1 mutations using affected embryo or gametes as proband.
Wang Y, Zhai F, Guan S, et al.
Journal of assisted reproduction and genetics 2021; (38(9)):2425-2434 doi:10.1007/s10815-021-02188-z.
PMID: 33939064 - 16
Maternal health and pregnancy outcomes in autosomal dominant tubulointerstitial kidney disease.
Bleyer AJ, Kidd KO, Williams AH, et al.
Obstetric medicine 2023; (16(3)):162-169 doi:10.1177/1753495X221133150.
PMID: 37720000 - 17
Identification of a novel UMOD mutation (c.163G>A) in a Brazilian family with autosomal dominant tubulointerstitial kidney disease.
Lopes LB, Abreu CC, Souza CF, et al.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica 2018; (51(3)):e6560 doi:10.1590/1414-431X20176560.
PMID: 29513881 - 18
Quality of life in patients with autosomal dominant tubulointerstitial kidney disease .
Bleyer AJ, Kidd K, Johnson E, et al.
Clinical nephrology 2019; (92(6)):302-311 doi:10.5414/CN109842.
PMID: 31587753
This page is for informational purposes only and does not constitute medical advice. A nephrologist and genetic counselor can help interpret your UMOD result and discuss family testing, pregnancy, and kidney-donation decisions.
Get notified when new evidence is published on familial juvenile hyperuricemic nephropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.